Table 3 APOE and CSF biomarker baseline descriptives by syndrome diagnosis
From: The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results
Subjective complaints | MCI | Dementia | |
|---|---|---|---|
APOE genotype | |||
APOE N | 159 | 208 | 294 |
e4 noncarrier | 96 (60%) | 97 (47%) | 137 (47%) |
e4 heterozygous | 51 (32%) | 90 (43%) | 124 (42%) |
e4 homozygous | 12 (8%) | 19 (9%) | 29 (10%) |
CSF biomarkers | |||
CSF biomarker N | 60 | 67 | 84 |
Amyloid-beta 1-42 | 817 ± 252 | 692 ± 290 | 610 ± 258 |
Total tau | 286 ± 170 | 473 ± 257 | 514 ± 277 |
Ptau | 38 ± 18 | 53 ± 26 | 57 ± 26 |